Yogesh M Kulkarni Selected Research

cyclo-VEGI

1/2018	A Lipidomics Approach to Identifying Key Lipid Species Involved in VEGF-Inhibitor Mediated Attenuation of Bleomycin-Induced Pulmonary Fibrosis.
1/2016	A proteomics approach to identifying key protein targets involved in VEGF inhibitor mediated attenuation of bleomycin-induced pulmonary fibrosis.
11/2015	Nitric oxide mediates bleomycin-induced angiogenesis and pulmonary fibrosis via regulation of VEGF.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yogesh M Kulkarni Research Topics

Disease

6	Neoplasms (Cancer) 06/2017 - 06/2010
3	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2018 - 11/2015
3	Breast Neoplasms (Breast Cancer) 06/2017 - 02/2012
1	Idiopathic Pulmonary Fibrosis 01/2018
1	Triple Negative Breast Neoplasms 06/2017
1	Lung Neoplasms (Lung Cancer) 01/2016
1	Experimental Melanoma 08/2012
1	Melanoma (Melanoma, Malignant) 08/2012

Drug/Important Bio-Agent (IBA)

4	Proteins (Proteins, Gene)FDA Link 01/2016 - 02/2012
3	cyclo-VEGIIBA 01/2018 - 11/2015
3	Bleomycin (Blenoxane)FDA LinkGeneric 01/2018 - 11/2015
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018 - 11/2015
2	Digitoxin FDA Link 06/2017 - 01/2016
1	LipidsIBA 01/2018
1	Estrogen ReceptorsIBA 06/2017
1	Cardiac GlycosidesIBA 06/2017
1	Biomarkers (Surrogate Marker)IBA 06/2017
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 11/2015
1	Interleukin-12 (IL 12)IBA 08/2012
1	Neoplasm Antigens (Tumor Antigens)IBA 08/2012
1	Amino Acids FDA Link 02/2012

Therapy/Procedure

5	Therapeutics 01/2018 - 06/2010
1	Molecular Targeted Therapy 09/2014
1	Immunotherapy 08/2012